A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Archives of Neurology

• Publication date

  2010-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/archneurol.2010.16PMID 20212229PMCID PMC6120585
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Thrombospondin‐1‐induced apoptosis of brain microvascular endothelial cells can be mediated by TNF‐R1

  2009cited by this paper
• Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

  2009cited by this paper
• Vascular endothelial growth factor activates the Tie family of receptor tyrosine kinases.

  2009cited by this paper
• Analysis of interleukin (IL)-8 expression in human astrocytomas: associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry.

  2009cited by this paper
• MicroRNA 21 Promotes Glioma Invasion by Targeting Matrix Metalloproteinase Regulators

  2008cited by this paper
• A phase 1 trial of 2 dose schedules of ABT‐510, an antiangiogenic, thrombospondin‐1‐mimetic peptide, in patients with advanced cancer

  2008cited by this paper
• Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

  2007cited by this paper
• Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma

  2007cited by this paper
• ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis

  2007cited by this paper
• Increased Expression of Thymidylate Synthetase (TS), Ubiquitin Specific Protease 10 (USP10) and Survivin is Associated with Poor Survival in Glioblastoma Multiforme (GBM)

  2006cited by this paper
• Perlecan, a candidate gene for the CAPB locus, regulates prostate cancer cell growth via the Sonic Hedgehog pathway

  2006cited by this paper
• Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling.

  2006cited by this paper
• Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the alphavbeta1 integrin and focal adhesion kinase signaling pathway.

  2006cited by this paper
• Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy.

  2005cited by this paper
• Low-density lipoprotein receptor-related protein contributes to the antiangiogenic activity of thrombospondin-2 in a murine glioma model.

  2005cited by this paper
• Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities.

  2005cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2

  2003cited by this paper
• CD36: a critical anti-angiogenic receptor.

  2003cited by this paper
• Inhibition of tumor growth by systemic treatment with thrombospondin‐1 peptide mimetics

  2002cited by this paper
• The Endothelial Receptor Tyrosine Kinase Tie1 Activates Phosphatidylinositol 3-Kinase and Akt To Inhibit Apoptosis

  2002cited by this paper
• A combinatorial role of angiopoietin-1 and orphan receptor TIE1 pathways in establishing vascular polarity during angiogenesis.

  2001cited by this paper
• The cell biology of thrombospondin-1.

  2000cited by this paper
• Expression of vascular endothelial growth factor-b in human astrocytoma.

  2000cited by this paper
• Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays.

  2000cited by this paper
• Expression of PECAM-1/CD31 Isoforms in Human Brain Gliomas

  1999cited by this paper
• Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat.

  1999cited by this paper
• Thrombospondin modulates basic fibroblast growth factor activities on endothelial cells.

  1992cited by this paper
• Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo

  1992cited by this paper
• Acidic and basic fibroblast growth factors are present in glioblastoma multiforme.

  1991cited by this paper
• Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor

  1990cited by this paper
• The low density lipoprotein receptor.

  1989cited by this paper

• Unraveling the intricate relationship between lipid metabolism and oncogenic signaling pathways

  2024cites this paper
• Preclinical Evaluation of CD36-Targeting Antiangiogenic Peptide ABT-510 for Near-Infrared Fluorescence Molecular Imaging of Colorectal Cancer.

  2023cites this paper
• The Recent Advance of Cell-Penetrating and Tumor-Targeting Peptides as Drug Delivery Systems Based on Tumor Microenvironment.

  2023cites this paper
• The Role of CD36 in Cancer Progression and Its Value as a Therapeutic Target

  2023cites this paper
• The multifaceted role of Matricellular Proteins in health and cancer, as biomarkers and therapeutic targets.

  2022cites this paper
• Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma

  2022cites this paper
• Progress of potential drugs targeted in lipid metabolism research

  2022cites this paper
• Anti-Angiogenic Therapy: Current Challenges and Future Perspectives

  2021cites this paper
• How cancer cells remodel lipid metabolism: strategies targeting transcription factors

  2021cites this paper
• Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma

  2021cites this paper
• Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma

  2020cites this paper
• Exploring Novel Molecular Targets for the Treatment of High-Grade Astrocytomas Using Peptide Therapeutics: An Overview

  2020cites this paper
• Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer Progression

  2020cites this paper
• The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential

  2019cites this paper
• Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far

  2019influential citation
• Peptides in clinical development for the treatment of brain tumors.

  2019cites this paper
• Reverting the molecular fingerprint of tumor dormancy as a therapeutic strategy for glioblastoma

  2018cites this paper
• Considerable Therapeutic Strategies for Treatment of Genetic Defects Govern Neurovascular Disease

  2018cites this paper
• Role of NOD- like Receptors in Glioma Angiogenesis: Insights into future therapeutic interventions.

  2017cites this paper
• Co-targeting the tumor endothelium and P-selectin-expressing glioblastoma cells leads to a remarkable therapeutic outcome

  2017cites this paper
• SCO-spondin oligopeptide inhibits angiogenesis in glioblastoma

  2017cites this paper
• Thrombospondins: A Role in Cardiovascular Disease

  2017cites this paper
• Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

  2016cites this paper
• The pituitary TGF b 1 system as a novel target for the treatment of resistant prolactinomas

  2016cites this paper
• Hydrophobic benzyl amines as supports for liquid‐phase C‐terminal amidated peptide synthesis: application to the preparation of ABT‐510

  2015cites this paper
• Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.

  2015cites this paper
• Impairment of medical decisional capacity in relation to Karnofsky Performance Status in adults with malignant brain tumor.

  2015cites this paper
• Extracellular Matrix Glycoprotein-Derived Synthetic Peptides Differentially Modulate Glioma and Sarcoma Cell Migration

  2015cites this paper
• Targeted Therapy in Gliomas

  2014cites this paper
• A Biomimetic Collagen Derived Peptide Exhibits Anti-Angiogenic Activity in Triple Negative Breast Cancer

  2014cites this paper
• Effect and Mechanism of Thrombospondin-1 on the Angiogenesis Potential in Human Endothelial Progenitor Cells: An In Vitro Study

  2014cites this paper
• Bevacizumab and other targeted agents in the upfront treatment of glioblastoma.

  2014cites this paper
• Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents.

  2014cites this paper
• Microenvironment and Immunology Immunosurveillance by Antiangiogenesis : Tumor Growth Arrest by T Cell – Derived Thrombospondin-1

  2014cites this paper
• A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies.

  2013cites this paper
• Oncolytic Virus Therapy in Combination with Chemotherapy for Ovarian Cancer

  2013cites this paper
• A systems biology view of blood vessel growth and remodelling

  2013cites this paper
• Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis.

  2013cites this paper
• Structure–Activity Relationship Study of Collagen‐Derived Anti‐Angiogenic Biomimetic Peptides

  2012cites this paper
• Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-β1 (TGF-β1).

  2012cites this paper
• Antiangiogenic therapies in glioblastoma multiforme

  2012cites this paper
• Targeting the Fas/FasL signaling pathway in cancer therapy

  2012cites this paper
• Glioma Stem Cells and their Therapy Resistance

  2012cites this paper
• The use of Thrombospondin-1 Mimetic Peptides for the Treatment of Epithelial Ovarian Cancer

  2012cites this paper
• Glioblastoma multiforme: overview of current treatment and future perspectives.

  2012cites this paper
• Caracterización del sistema TGF-ß1 hipofisario: en búsqueda de un blanco terapéutico para prolactinomas resistentes a agonistas dopaminérgicos

  2012cites this paper
• Anti-angiogenic gene therapy in the treatment of malignant gliomas.

  2012influential citation
• Antiangiogenic and anticancer molecules in cartilage

  2012cites this paper
• Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2.

  2012cites this paper
• Collagen IV and CXC chemokine-derived antiangiogenic peptides suppress glioma xenograft growth

  2012cites this paper
• New Agents Targeting Angiogenesis in Glioblastoma

  2011cites this paper
• Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches

  2011cites this paper
• Thrombospondin-1 Modulates the Angiogenic Phenotype of Human Cerebral Arteriovenous Malformation Endothelial Cells

  2011cites this paper
• Rational Design and Development of Anti- Angiogenic Protein Agents

  2011cites this paper
• Therapies using anti-angiogenic peptide mimetics of thrombospondin-1

  2011cites this paper
• Evolving strategies: future treatment of glioblastoma

  2011cites this paper
• Anti-angiogenic peptides for cancer therapeutics.

  2011cites this paper
• The Role of Angiopoietin-2 in Signaling Through the Endothelial Receptor Tyrosine Kinase Tie1

  2010cites this paper
• Antiangiogenic and anticancer molecules in cartilage Antiangiogenic and anticancer molecules in cartilage

  year unknowncites this paper